<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3EFE7832-18E5-4B3B-B70C-E241C563AEDF"><gtr:id>3EFE7832-18E5-4B3B-B70C-E241C563AEDF</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Kendall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/079C6C80-92CF-40EF-A68C-596A1C05045F"><gtr:id>079C6C80-92CF-40EF-A68C-596A1C05045F</gtr:id><gtr:firstName>D</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Barrett</gtr:surname><gtr:orcidId>0000-0001-6900-9474</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E8CADCCC-FDBF-4D6A-96B4-D736BF78B0BA"><gtr:id>E8CADCCC-FDBF-4D6A-96B4-D736BF78B0BA</gtr:id><gtr:firstName>Maurice</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Elphick</gtr:surname><gtr:orcidId>0000-0002-9169-0048</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7D72B01B-ACC6-441F-B961-118B634A4F27"><gtr:id>7D72B01B-ACC6-441F-B961-118B634A4F27</gtr:id><gtr:firstName>Victoria</gtr:firstName><gtr:surname>Chapman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DBBB56B5-D3C6-4F63-A3BB-8B27C7F21DE3"><gtr:id>DBBB56B5-D3C6-4F63-A3BB-8B27C7F21DE3</gtr:id><gtr:firstName>Gregory J.</gtr:firstName><gtr:surname>Michael</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401647"><gtr:id>6434E678-EE63-4030-839D-47567618997E</gtr:id><gtr:title>Cannabinoid CB2 receptors: a novel target for analgesics in neuropathic pain states</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401647</gtr:grantReference><gtr:abstractText>Chronic pain states are difficult to treat and novel, side-effect free, analgesics are needed. Cannabis-like compounds (cannabinoids) act at CB1 and CB2 receptors, which are present in peripheral and brain tissue, and produce analgesic effects in animal models of chronic pain. Activation of CB2 receptors is not associated with side-effects and, as a result, CB2 receptors are a potential novel analgesic target for chronic pain states. This project will evaluate whether levels of cannabinoid receptors, and the endogenous compounds that activate these receptors, are modified in the spinal cord and brain in chronic pain states and if CB2 receptors in the spinal cord and brain are a novel analgesic target for these conditions.</gtr:abstractText><gtr:technicalSummary>Cannabinoid based drugs have therapeutic potential for chronic pain states, such as neuropathic pain. Mixed CB1 and CB2 receptor agonists and CB1 selective agonists produce CNS mediated side-effects, limiting clinical use. 
Evidence suggests that up-regulated CB2 receptors in the spinal cord and brain may be a novel therapeutic target for neuropathic pain. CB2 receptor agonists are not associated with side-effects. 
Hypothesis: Up-regulated CB2 receptors and endocannabinoids in the spinal cord and thalamus are therapeutic targets for cannabinoid-based treatments of neuropathic pain states. 

1: What is the impact of peripheral nerve injury on cannabinoid CB2 receptor expression and levels of endocannabinoids in the spinal cord and brain? 
We will measure the density and functional coupling of CB2 receptors in the spinal cord and brain of neuropathic rats (selective spinal nerve ligation). Double labelling immunohistochemistry will determine the cellular localization of CB2 receptors.

Up-regulated CB2 receptors are potential targets for endocannabinoids in the spinal cord and brain, but it is not known whether levels of endocannabinoids are increased in models of neuropathic pain states. This question will be addressed by the measurement of levels of endocannabinoids in the spinal cord and brain of neuropathic rats by liquid chromatography coupled to tandem electrospray ionisation mass spectrometry. 

2: Do endocannabinoids provide tonic inhibitory control of nociceptive responses in neuropathic rats? 

Endocannabinoids provide tonic inhibitory control of nociception in models of acute pain and we will determine whether this is important in neuropathic pain. If this is the case, pharmacological manipulation of endocannabinoid metabolism may provide an alternative therapeutic approach for neuropathic pain. 
Effects of spinal and thalamic injection of the CB2 receptor antagonist SR144528 on mechanical and cold allodynia will be studied. If endocannabinoids dampen down aberrant nociceptive behaviour in neuropathic rats, we predict that SR144528 will exacerbate mechanical and cold allodynia. 

3: Are up-regulated CB2 receptors in the spinal cord and thalamus a target for the treatment of neuropathic pain states? 
Assessment of the inhibitory effects of spinal and thalamic administration of CB2 receptor agonist JWH-133 on mechanical and cold-evoked nociceptive behaviour and neuronal firing in neuropathic rats will determine the functional importance of up-regulated CB2 receptors in the integrated system. 
This project will determine whether spinal cord and brain CB2 receptors are therapeutic targets for neuropathic pain states. These results will have important implications for cannabinoid-based analgesia approaches for the treatment of neuropathic pain.</gtr:technicalSummary><gtr:fund><gtr:end>2009-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>379118</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interaction with local schools</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>46492B0C-06FF-4F8E-8139-F3886FBE2C88</gtr:id><gtr:impact>Link for enabling science students from a local school to undertake work placements at the University.

Improve links between local Schools and research in the Pharmaceutical sector within the University.</gtr:impact><gtr:outcomeId>67A8EE2B1CE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of rabbit antibodies to rat CB2 and mouse CB2. We have also provided other labs with CB2 antigen peptides to enable generation of mouse monoclonal antibodies to CB2.</gtr:description><gtr:id>2BD0EA77-4C4A-41F3-9214-0FF63FA22BA2</gtr:id><gtr:impact>The Elphick lab at QMUL generated these antibodies and they will be made available to the research community when the first paper reporting their development and characterisation has been published. Previously, other antibodies to cannabinoid-related proteins (e.g. CB1, NAPE-PLD, CRIP1a) have been generated in the Elphick lab and these are regularly provided to other labs on request.</gtr:impact><gtr:outcomeId>F8490138A46</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CB2 antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>52BCE09A-D113-4277-8591-D810CB9C9918</gtr:id><gtr:title>Simultaneous tissue profiling of eicosanoid and endocannabinoid lipid families in a rat model of osteoarthritis.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94d96d9df6507287daf57ed12bd916f0"><gtr:id>94d96d9df6507287daf57ed12bd916f0</gtr:id><gtr:otherNames>Wong A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>doi_55f983983a238b29</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77775E43-2D8C-4F72-8ABE-16816D52BBFB</gtr:id><gtr:title>Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain.</gtr:title><gtr:parentPublicationTitle>Molecular neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcc55d82967389a257081c86bc1d561f"><gtr:id>bcc55d82967389a257081c86bc1d561f</gtr:id><gtr:otherNames>Jhaveri MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0893-7648</gtr:issn><gtr:outcomeId>963B0D33342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9252C242-B056-4F95-AB65-7A744E2DBE3F</gtr:id><gtr:title>Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35d1748c55b0835425c7f358c3ed9f32"><gtr:id>35d1748c55b0835425c7f358c3ed9f32</gtr:id><gtr:otherNames>Sagar DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>GzyMa6ychbw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4A0B2E3-D8B1-4E2A-B930-D079269B0125</gtr:id><gtr:title>Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcc55d82967389a257081c86bc1d561f"><gtr:id>bcc55d82967389a257081c86bc1d561f</gtr:id><gtr:otherNames>Jhaveri MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>34875ED3732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF55BD14-1AE6-49C7-BFBF-496DB67794C0</gtr:id><gtr:title>Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f59425c8a1a8c3d69ca120339001173f"><gtr:id>f59425c8a1a8c3d69ca120339001173f</gtr:id><gtr:otherNames>Guasti L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>D892DF97CFB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D2E5B1A-5E41-410E-8366-BA55EEC7B592</gtr:id><gtr:title>Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcc55d82967389a257081c86bc1d561f"><gtr:id>bcc55d82967389a257081c86bc1d561f</gtr:id><gtr:otherNames>Jhaveri MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>865C3B4886D</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401647</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>